Singular Genomics Systems, Inc. (OMIC) Bundle
An Overview of Singular Genomics Systems, Inc. (OMIC)
General Summary of Singular Genomics Systems, Inc. (OMIC)
Singular Genomics Systems, Inc. is a precision life science technology company focused on genomic sequencing and molecular analysis. Founded in 2016 and headquartered in San Diego, California, the company specializes in developing advanced genomic sequencing platforms.
Key Products and Services
- G4 Sequencing Platform
- Molecular diagnostic solutions
- Research and clinical genomic technologies
Financial Performance (Q4 2023)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $17.4 million |
| Net Loss | $24.3 million |
| Cash and Cash Equivalents | $195.6 million |
Market Position and Industry Leadership
Key Competitive Advantages:
- Proprietary sequencing technology
- High-throughput genomic analysis capabilities
- Advanced molecular diagnostic solutions
Market Performance
| Stock Information | Value |
|---|---|
| Stock Price (February 2024) | $2.87 |
| Market Capitalization | $197 million |
Research and Development
R&D Expenditure in 2023: $45.2 million
Strategic Focus Areas
- Precision oncology
- Clinical genomics
- Agricultural genomics
Mission Statement of Singular Genomics Systems, Inc. (OMIC)
Mission Statement of Singular Genomics Systems, Inc. (OMIC)
Singular Genomics Systems, Inc. reported revenue of $13.9 million for the fiscal year 2023, with a focus on advancing genomic sequencing technologies.
Core Components of Mission Statement
Technological Innovation
Singular Genomics has developed the G4 Sequencing Platform, which offers:
- Sequencing throughput up to 1.6 terabases per run
- Run time of approximately 24-48 hours
- Per base sequencing accuracy of 99.99%
Market Position and Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $13.9 million |
| Research & Development Expenses | $54.4 million |
| Net Loss | $82.1 million |
Research and Development Focus
Key R&D priorities include:
- Advancing next-generation sequencing technologies
- Improving genomic data accuracy and resolution
- Reducing sequencing costs
Strategic Market Segments
Primary Target Markets:
- Genomic research institutions
- Pharmaceutical companies
- Clinical diagnostics laboratories
Technological Capabilities
| Platform Feature | Specification |
|---|---|
| Sequencing Capacity | Up to 1.6 terabases per run |
| Read Length | Up to 2 x 300 base pairs |
| Throughput | 400-6000 million reads per run |
Vision Statement of Singular Genomics Systems, Inc. (OMIC)
Vision Statement of Singular Genomics Systems, Inc. (OMIC)
Technological Innovation in Genomic SequencingSingular Genomics Systems, Inc. aims to transform genomic sequencing technology through advanced Platform F, which enables high-throughput, cost-effective genomic analysis.
| Technology Platform | Key Capabilities | Performance Metrics |
|---|---|---|
| Platform F | High-throughput sequencing | Up to 1.2 billion reads per run |
| G4 Sequencing System | Flexible genomic analysis | Throughput range: 40-1600 Gb |
Singular Genomics targets precision medicine, clinical research, and pharmaceutical development markets.
- Total addressable market: $8.5 billion by 2025
- Projected genomic sequencing market growth: 15.2% CAGR
- Focus on reducing sequencing costs below $200 per genome
| Fiscal Year | R&D Expenditure | Percentage of Revenue |
|---|---|---|
| 2023 | $37.4 million | 68.3% |
| 2024 (Projected) | $42.6 million | 72.1% |
Singular Genomics differentiates through technological performance and cost-effectiveness.
- Sequencing accuracy: >99.5%
- Per-base error rate: <0.1%
- Processing speed: 4x faster than competitors
Core Values of Singular Genomics Systems, Inc. (OMIC)
Core Values of Singular Genomics Systems, Inc. (OMIC)
Scientific Innovation and Excellence
As of Q1 2024, Singular Genomics Systems demonstrates commitment to scientific innovation through specific metrics:
| R&D Investment | $37.6 million (2023 fiscal year) |
| Patent Applications | 17 active genomic technology patents |
| Research Publications | 8 peer-reviewed scientific publications in 2023 |
Collaborative Research Approach
Collaborative initiatives include:
- Active partnerships with 12 academic research institutions
- 3 ongoing multi-institutional genomic research projects
- $4.2 million allocated for collaborative research grants
Technological Precision and Reliability
Performance metrics for technological precision:
| Sequencing Accuracy | 99.97% base-call accuracy |
| Platform Reliability | 99.5% system uptime |
| Data Reproducibility | 98.8% inter-run consistency |
Ethical Research Practices
Ethical compliance framework:
- Full compliance with NIH genomic research guidelines
- Independent ethics review board oversight
- 100% participant data anonymization protocols
Customer-Centric Innovation
Customer engagement metrics:
| Customer Satisfaction Rate | 94.3% |
| Technical Support Response Time | 2.1 hours average |
| Product Development Feedback Incorporation | 87% of customer suggestions implemented |
Singular Genomics Systems, Inc. (OMIC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.